Tazicef
Product Images NDC 0409-5093

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tazicef (NDC 0409-5093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Tazicef 01)

Chemical structure diagram of the active ingredient in TAZICEF by Hospira, Inc. The structure includes multiple heterocyclic rings, an amino group, carboxylic acids, and a pyridinium moiety with five water molecules of hydration (pentahydrate).*

FDA Label Image

Tazicef 01a

FDA Label Image

Fig 1 And 2 (Tazicef 02)

FDA Label Image

Fig 3 And 4 (Tazicef 03)

Instructional line-drawing illustration depicting the removal of a tamper-evident ring from a TAZICEF medication bottle. Figure 1 shows a hand pulling the ring downward to detach it from the bottle cap. Figure 2 shows the cap being lifted upward after ring removal, demonstrating how to open the bottle.*

FDA Label Image

Fig 5 And 6 (Tazicef 04)

Illustrative diagrams depicting hands interacting with a medical fluid container, likely demonstrating steps to prepare or use the container. The images show hand placement on the container and manipulations of its cap or seal, relevant to TAZICEF by Hospira, Inc.*

FDA Label Image

Hospira Logo (Tazicef 05)

Instructional illustrations showing how to administer medication from a flexible pouch. Figure 5 depicts one hand holding the pouch while the other hand removes a cap. Figure 6 shows the cap fully removed with the pouch held in a similar manner. These steps are part of the preparation for using TAZICEF from Hospira, Inc.*

FDA Label Image

Principal Display Panel (1 gram Vial Label)

FDA Label Image

Principal Display Panel (1 gram Vial Carton)

TAZICEF ceftazidime for injection, USP label showing 1 g/vial equivalent for intravenous infusion only. Packaged in a single-dose ADD-Vantage vial, the label includes storage instructions and manufacturing details by Sandoz GmbH for Hospira, Inc. in Lake Forest, IL. The label features directions for light protection and room temperature storage.*

FDA Label Image

Principal Display Panel (2 gram Vial Label)

TAZICEF 1 g vial ceftazidime for injection USP packaging label. Contains 25 single-dose ADD-Vantage vials intended for intravenous infusion only. Manufactured for Hospira, Inc., featuring red and green highlighted dosage and administration information. Includes barcode and QR code on the label panels.*

FDA Label Image

Principal Display Panel (2 gram Vial Carton)

TAZICEF ceftazidime for injection, USP 2 g per vial. Label states it is for intravenous infusion only and is a single-dose ADD-Vantage vial. The label includes manufacturer information for Hospira, Inc. and storage instructions.*

FDA Label Image

Tazicef 10

TAZICEF Ceftazidime for Injection, USP 2 g/vial, packaging label for 10 single-dose ADD-Vantage vials. The label indicates the product is for intravenous infusion only and is labeled Rx only. Manufactured by Hospira, Inc., the packaging includes storage and dosage details along with the NDC 0409-5093-11.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.